New Tests Monitor Thyroid Cancer

Editor's Note: Contributing Editor Ricki Lewis was diagnosed with thyroid cancer in 1993 and had standard treatment. She will be taking a recently approved test this summer and hopes to participate in the clinical trial of another, both discussed below. Michael Levine When a lump in the neck turns out to be thyroid cancer, many doctors announce, "If you had to get cancer, this is the one to get." Fortunately, treatment is straightforward and effective, but follow-up testing can be uncomfort

Written byRicki Lewis
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Focus on Cancer Research Editor's Note: Contributing Editor Ricki Lewis was diagnosed with thyroid cancer in 1993 and had standard treatment. She will be taking a recently approved test this summer and hopes to participate in the clinical trial of another, both discussed below.

Michael Levine
When a lump in the neck turns out to be thyroid cancer, many doctors announce, "If you had to get cancer, this is the one to get." Fortunately, treatment is straightforward and effective, but follow-up testing can be uncomfortable because it requires a hypothyroid state. Now two new tests promise to ease the lifelong monitoring necessary to detect recurrence and identify patients most likely to benefit from follow-up procedures.

Each year in the United States, about 20,000 people are diagnosed with thyroid cancer, and 1,100 die of it. "This requires patients to be monitored at frequent intervals for the rest of their lives," says Michael Levine, a professor ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies